Digital health company Global Kinetics has established technology partnership with uMotif for the trials of Parkinson's disease.

The partnership will provide a comprehensive, validated and simple to use data capture platform to enhance the treatment and understanding of Parkinson's disease.

The firms combined Parkinson's platform will enable to measure and demonstrate the value of medications, devices and services in Parkinson's disease ranging from clinical to commercial phases of development.

Parkinson's platform is based on two clinically validated systems for clinical trials, including Global Kinetics' Personal KinetiGraph (PKG) system and uMotif's mobile and web platform.

The PKG system integrates a wrist-worn device and cloud-based algorithms to objectively and continuously record movement symptoms such as bradykinesia, dyskinesia, tremor, and relating them to medication timing, sleep and exercise.

The uMotif's mobile and web platform for trial data capture will enable electronic capture of patient reported data, comprising of e-consent, patient reported outcomes (ePRO) and clinical outcomes assessments (eCOA), diaries and symptom tracking

Global Kinetics’ PKG system is currently in use in around 200 specialist clinics across 17 countries. The uMotif platform has been developed for patient-centred data capture in Parkinson's Disease and 15 other clinical conditions.

Both firms are already providing commercial product development services for multinational and small pharmaceutical and device companies in Parkinson's and other indications.

Global Kinetics president and CEO Timothy Still said: "This exciting partnership with uMotif represents a significant strategic move for our company alongside our fast growing clinical product for routine management of Parkinson's disease.

uMotif CEO Bruce Hellman said: "The past few years have seen rapid growth in the use of the uMotif platform, chosen by major world-leading clients and partners to capture high quality patient-reported data for global research projects and trials.”